GH Research (NASDAQ:GHRS) Shares Gap Down – What’s Next?

GH Research PLC (NASDAQ:GHRS) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.32, but opened at $15.65. GH Research shares last traded at $15.06, with a volume of 844,915 shares changing hands.

Analyst Ratings Changes

Several analysts have issued reports on the company. Canaccord Genuity Group dropped their price target on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th.

GH Research Stock Performance

The company has a market cap of $780.71 million, a P/E ratio of -18.99 and a beta of 0.93. The company has a fifty day moving average price of $8.73 and a two-hundred day moving average price of $8.96.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. raised its position in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).